Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Paricalcitol and Hydroxychloroquine (PH) Combination With Gemcitabine and Nab-Paclitaxel in Advanced or Metastatic Pancreatic Cancer

NCT04524702 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT04524702
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04524702 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Paricalcitol and Hydroxychloroquine (PH) Combination With Gemcitabine and Nab-Paclitaxel in Advanced or Metastatic Pancreatic Cancer
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Completed
Start date
September 14, 2020
Completion date
June 6, 2023
Enrollment
10 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced pancreatic adenocarcinoma, metastatic pancreatic adenocarcinoma, stage iv pancreatic cancer ajcc v8